ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 167,50
0,00%
Dow Jones
40 003,59
0,34%
DAX
18 704,42
-0,11%
Brent Oil
83,895
0,36%
Bitcoin
67 135,34
1,30%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Biogen Inc (BIIB)

  7. Biogen Inc (BIIB) Actualités

BIIB

Biogen (BIIB)

Biogen Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:BIIB
DateHeureSourceTitreSymboleSociété
16/05/202413h30GlobeNewswire Inc.Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral SclerosisNASDAQ:BIIBBiogen Inc
16/05/202413h30PR Newswire (US)Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral SclerosisNASDAQ:BIIBBiogen Inc
15/05/202401h33GlobeNewswire Inc.Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track StatusNASDAQ:BIIBBiogen Inc
15/05/202401h30PR Newswire (US)Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track StatusNASDAQ:BIIBBiogen Inc
02/05/202413h30GlobeNewswire Inc.Biogen Reports Progress on Corporate Responsibility PrioritiesNASDAQ:BIIBBiogen Inc
01/04/202401h30PR Newswire (US)Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDANASDAQ:BIIBBiogen Inc
06/03/202413h30GlobeNewswire Inc.New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene TherapyNASDAQ:BIIBBiogen Inc
04/03/202422h15GlobeNewswire Inc.Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual MeetingNASDAQ:BIIBBiogen Inc
27/02/202401h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
23/02/202413h00GlobeNewswire Inc.Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMPNASDAQ:BIIBBiogen Inc
22/02/202416h12Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BIIBBiogen Inc
13/02/202413h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BIIBBiogen Inc
13/02/202401h11Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:BIIBBiogen Inc
12/02/202422h06GlobeNewswire Inc.Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s AtaxiaNASDAQ:BIIBBiogen Inc
09/01/202423h52Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
19/12/202313h30GlobeNewswire Inc.Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European CommissionNASDAQ:BIIBBiogen Inc
15/12/202315h05GlobeNewswire Inc.CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative DiseaseNASDAQ:BIIBBiogen Inc
14/12/202312h30Business WireZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.NASDAQ:BIIBBiogen Inc
08/11/202322h35Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BIIBBiogen Inc
08/11/202314h19IH Market NewsKeep An Eye Out: Pre-Market Movers And Analyst RecommendationsNASDAQ:BIIBBiogen Inc
06/11/202323h44KR Market News월스트리트 상승, 시장은 연준 연사 및 재무부 경매 주목NASDAQ:BIIBBiogen Inc
06/11/202313h30GlobeNewswire Inc.Biogen Appoints Monish Patolawala to its Board of DirectorsNASDAQ:BIIBBiogen Inc
26/10/202313h08IH Market NewsThursday’s Wall Street Highlights: Ford, Morgan Stanley, Align Technology, Endeavor, and moreNASDAQ:BIIBBiogen Inc
25/10/202323h26GlobeNewswire Inc.Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The Clinical Trials On AlzNASDAQ:BIIBBiogen Inc
25/10/202323h25PR Newswire (US)EISAI PRESENTS NEW LEQEMBI® (LECANEMAB-IRMB) INVESTIGATIONAL SUBCUTANEOUS FORMULATION INTERIM STUDY RESULTS AND CLINICAL IMPROVEMENT DATA IN EARLIER STAGES OF EARLY ALZHEIMER'S DISEASE FROM ADDITIONAL ANALYSES OF CLARITY AD AT THE CLINICAL TRIALS ON ALZHENASDAQ:BIIBBiogen Inc
25/10/202316h51GlobeNewswire Inc.New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s DiseaseNASDAQ:BIIBBiogen Inc
24/10/202315h30PR Newswire (US)LEQEMBI® (lecanemab-irmb) NAMED ONE OF TIME's BEST INVENTIONS OF 2023NASDAQ:BIIBBiogen Inc
19/10/202313h30GlobeNewswire Inc.Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 MeetingNASDAQ:BIIBBiogen Inc
04/10/202314h15IH Market NewsKeep An Eye Out: Pre-Market Movers And RecommendationsNASDAQ:BIIBBiogen Inc
29/09/202322h49Dow Jones NewsBiogen's Tofidence Intravenous Formulation Gets FDA ApprovalNASDAQ:BIIBBiogen Inc
 Showing the most relevant articles for your search:NASDAQ:BIIB

Dernières Valeurs Consultées

TG
K27
Kodiak Sciences
TG
CVS
CVS Health
USOTC
JSCPY
JSR (PK)
EU
BE0002873546
Brussels Capital Bond un...
TG
MUR1
Murata Manufacturing
USOTC
VLTLF
Volt Lithium (QB)
NASDAQ
VGLT
Vanguard Long Term Treas...
COIN
RADGBP
Radicle
EU
ACAMB
Credit Agricole 1.4% 26j...
USOTC
BYLOF
Big Yellow (PK)
ASX
AOM
Australia Oriental Minerals
USOTC
JSBL
JS Beauty Land Network T... (CE)
TG
CYL
Artivion
TG
1QK
Aedas Homes
LSE
EUSV
Spdr Eur Sc Val
TG
ILU
Illumina Inc Dl 01
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés